Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 7
Submit an article Journal homepage
477
Views
63
CrossRef citations to date
0
Altmetric
Review

Clinical investigations of Toll-like receptor agonists

Thomas Meyer University of Hamburg, University Hospital Hamburg-Eppendorf, Institute of Medical Microbiology, Virology and Hygiene, Martinistrasse 52, 20246 Hamburg, Germany +49 40 42803 2145; +49 40 42803 8420; [email protected]
, PhD &
Eggert Stockfleth University of Berlin, Department of Dermatology, Skin Cancer Center Charite (HTCC), Chariteplatz 1, 10117 Berlin, Germany
, MD
Pages 1051-1065 | Published online: 12 Jun 2008

Bibliography

  • Medzhitov R, Janeway CA. Innate immunity. N Engl J Med 2000;343:338-44
  • Janeway CA, Medzhitov R. Innate immune recognition. Ann Rev Immunol 2002;20:197-216
  • Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7
  • Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol 2002;14:123-8
  • Carneiro LAM, Magalhaes JG, Tattoli I, et al. Nod-like proteins in inflammation and disease. J Pathol 2008;214:136-48
  • Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39-44
  • Bottazzi B, Garlanda C, Salvatori G, et al. Pentraxins as a key component of innate immunity. Curr Opin Immunol 2006;18:10-5
  • O'Neill JA. Signal transduction pathways activated by the IL-1 receptor/Toll-like recptor superfamily. Curr Top Microbiol Immunol 2002;270:47-62
  • Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002;14:103-10
  • Travassos LH, Giardin SE, Philpott DJ, et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep 2004;5:1000-6
  • Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;410:1099-103
  • O'Neill L. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006;18:3-9
  • Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5
  • Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001;2:675-80
  • Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002;270:81-92
  • Yamamoto M, Sato S, Moro K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002;169:6668-72
  • Uematsu S, Sato S, Yamamoto M, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR) 7- and TLR 9-mediated interferon-(alpha) induction. J Exp Med 2005;201:915-23
  • Johnson GB, Brunn GJ, Tang AH, Platt JL. Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol 2003;24:19-24
  • Beg AA. Endgenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002;23:509-12
  • Hemmi H, Kaisho O, Takeuchi S, et al. Small anti-viral compounds acitivate immune cells via the TLR7 MyD88-dependent signalling pathway. Nat Immunol 2002;3:196-200
  • Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R848. Nat Immunol 2002;3:499
  • Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31
  • Lund JM, Alexopoulou L, Sato A, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004;101:5598-603
  • Testerman TL, Gerster JF, Imbertsen LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58:365-72
  • Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27:571-7
  • Garland SM. Imiquimod. Curr Opin Infect Dis 2003;16:85-9
  • Schön MP, Schön M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signalling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006;126:1338-47
  • Kanneganti TD, Ozoren N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006;440:233-6
  • Meyer T, Nindl I, Schmook T, et al. Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 2003;149(Suppl 66):9-13
  • Schön M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-49
  • Urosevic M, Maier T, Benninghoff B, et al. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139:1325-32
  • Berman B, Sullivan TP, Araujo T, Nadji T. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquiomod 5% cream or vehilcle. Br J Dermatol 2003;149(Suppl 66):59-61
  • Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient applied immune response modifier for trteatment of external warts. Antimicrob Agents Chemother 1998;42:789-94
  • Beutner KR, Spruance SL, Hougham AJ, et al. Treatmant of genital warts with an immune response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9
  • Edwards L, Ferenzy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30
  • Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 2001;1:3
  • Fife KH, Ferenzy A, Douglas JM Jr, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week once daily, twice daily, or three times a day. Sex Transm Dis 2001;28:226-31
  • Yan J, Chen SL, Wang HN, Wu TX. Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of Condylomata acuminata. Dermatology 2006;213:218-23
  • Centers for Disease Control and Prevention: 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1998;47:88-95
  • Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% cream (Aldara TM). Expert Opin Invest Drugs 1998;7:437-49
  • Schöfer H, van Ophoven A, Henke U, et al. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006;16:642-8
  • Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis 1998;178:858-61
  • Gilson RJ, Shupack JL, Friedman-Kien AE, et al. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS 1999;13:2397-404
  • Brown VL, Atkins CL, Ghali L, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005;141:985-93
  • Ulrich C, Bichel J Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(Suppl 2):25-31
  • Cusini M, Samaso F, Zerboni R, et al. 5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS 2004;15:17-20
  • Kaspari M, Gutzmer R, Kaspari T, et al. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 2002;147:757-9
  • Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157:133-41
  • Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007;57:265-8
  • Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratoses: a meta analysis of randomized controlled trials. J Am Acad Dermatol 2006;55:537-8
  • Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502
  • Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47:571-7
  • Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21
  • Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141:467-73
  • Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126:1251-5
  • Stockfleth E, Christophers, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004;140:1542
  • Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomized study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157(Suppl 2):34-40
  • Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:25-8
  • Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2003;353:2712-3
  • Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91
  • Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 1986;15:437-43
  • Beutner Geisse JK, Helmann D, Fox TL, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7
  • Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001;44:807-13
  • Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002;47:390-8
  • Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227-36
  • Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 2005;152:939-47
  • Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005;15:374-81
  • Quirk C, Gebauer K, Owens M, Stampone P. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol 2006;47:258-65
  • Sparling JD, Checketts SR, Chapman MS. Imiquimod for plantar and periungual warts. Cutis 2001;68:397-9
  • Cutler K, Kagen MH, Don PC, et al. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus. Acta Derm Venereol 2000;80:134-5
  • Rinne D, Linhart C, Schöfer H. Lip papillomatosis in immunodeficiency: therapy with imiquimod. Br J Dermatol 2000;142:196-7
  • Hengge U, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and mollusca contagiosa. Br J Dermatol 2000;143:1026-31
  • Gayed SL. Topical imiquimod cream 5% for resistant perianal warts in renal transplant patients. Int J STD AIDS 2002;13:501-3
  • Schmook T, Nindl I, Ulrich C, et al. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol 2003;149(Suppl 66):20-4
  • Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod-treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol 2006;142:1438-44
  • Kreuter A, Potthoff A, Brockmeyer NH, et al. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol 2008; online publication doi:10.1038/jid.2008.24
  • Bernstein DI, Harrison CJ, Tomai MA, Miller RL. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis 2001;183:844-9
  • Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistent cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51
  • Harrison CJ, Lenski L, Voychechovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res 1998;10:209-23
  • Miller RL, Imbertson LM, Reiter MJ, Gerster JF. Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral Res 1999;44:31-42
  • Morrey JD, Day CW, Julander JG, et al. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 2004;15:101-9
  • Clejan S, Mandrea E, Pandrea IV, et al. Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infection. J Cell Mol Med 2005;9:457-61
  • Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimes. Arch Dermatol 2002;138:1165-71
  • Peris K, Campione E, Micantonio T, et al. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg 2005;31:318-23
  • Schiessl C, Wolber C, Tauber M, et al. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up. J Drugs Dermatol 2007;6:507-13
  • Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol 2002;12:569-72
  • Wu JK, Siller G, Whitehead K. Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas J Dermatol 2003;44:123-5
  • Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002;46:545-8
  • Konstantopoulou M, Lord MG, Macfarlane AW. Treatment of invasive squamous cell carcinoma with 5% imiquimod cream. Dermatol Online J 2006;13:10
  • Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001;44:462-70
  • Peris K, Micantonio T, Fargnoli MC, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006;55:324-7
  • Goh MS. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol 2006;47:186-8
  • Martin-Garcia RF. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg 2005;31:371-4
  • Stockfleth E, Röwert J, Arndt R, et al. Detection of HPV in stucco keratosis and successful treatment with imiquimod 5%. Br J Dermatol 2000;143:846-50
  • Dendorfer M, Oppel T, Wollenberg A, Prinz JC. Topical treatment with imiquimod may induce regression of facial keratoakanthoma. Eur J Dermatol 2003;13:80-2
  • Peris K, Micantonio T, Fargnoli MC. Successful treatment of keratoacanthoma and actinic keratoses with imiquimod 5% cream. Eur J Dermatol 2003;13:413-4
  • Aroni K, Mastoraki A, Agrogiannis G, et al. Successful treatment of keratoacanthoma centrifugum marginatum with local application of imiquimod cream. Int J Dermatol 2007;46:1321-2
  • Zamponga JC, Flowers FP, Roth WI, Hassenein AM. Treatment of primary limited curaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. J Am Acad Dermatol 2002;47(Suppl 4):S229-35
  • Quian Z, Zeitoun NC, Shieh S, et al. Successful treatment of extramammary Paget's disease with imiquimod. J Drugs Dermatol 2003;2:73-6
  • Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000;143:843-5
  • Rajpar SF, Mardsen JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006;155:653-6
  • Steinman A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6
  • Wolf IH, Smolle J, Binder B, et al. Topical imiquimod in the treatment of metastatic melanoma to the skin. Arch Dermatol 2003;139:273-6
  • Ugurel S, Wagner A, Pfohler C, et al. Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. Br J Dermatol 2002;147:621-4
  • Dummer R, Urosevic M, Kempf W, et al. Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides. Dermatology 2003;207:116-8
  • Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007;56:882-6
  • Janssen K, Lucker GP, Houwing RH, van Rijssel R. Epidermodysplasia verruciformis: unsuccessful therapeutic approach with imiquimod. Int J Dermatol 2007;46(Suppl 3):45-7
  • Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers R-848 and imiquimod. Cell Immunol 1999;191:10-9
  • Ahonen CL, Gibson SJ, Smith RM, et al. Dendritic cell maturation and subsequent enhanced T cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol 1999;197:62-72
  • Tomai MA, Gibson SJ, Imbertson LM, et al. Immunomodulating and antiviral activities of the imidazochinolines S-28643. Antivir Res 1995;28:253-64
  • Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001;184:196-200
  • Wu JJ, Huang DB, Tyring SK. Resiquimod : a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 2004;64:79-83
  • Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007;195:1324-31
  • Tomai MA, Miller RL, Lipson KE, et al. Immune response modifiers: Imiquimod and future drugs for modulating the immune response. Drug Discov Today 2006;3:343-52
  • Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94
  • Krieg AM. Anti-infective applications of Toll-like receptor 9 agonists. Proc Am Thorac Soc 2007;4:289-94
  • Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2005;5:987-95
  • Liu YJ. IPC: professional type 1 interferon producing cells and plasmacytoid dendritic cell precursors. Ann Rev Immunol 2005;23:275-306
  • McHutchinson JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C. Hepatology 2007;46:1341-9
  • Schmidt C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 2007;25:825-6
  • Stern BV, Boehm BO, Tary-Lehmann M. Vaccination with tumor peptide in CpG adjuvant proteins via IFN-gamma-dependent CD4 cell immunity. J Immunol 2002;168:6099-105
  • Miconnet I König S, Speiser D. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol 2002;168:1212-8
  • Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003;9:2693-700
  • Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307
  • Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin Exp Immunol 1980;39:435-41
  • Cox FE, Liew FY. T cell subsets and cytokines in parasitic infections. Immunol Today 1992;13:445-8
  • Merritt K, Johnson AG. Studies on the adjuvant action of bacterial endotoxins of antibody formation VI. Enhancement of antibody formation by nucleic acids. J Immunol 1965;94:416-22
  • Ellouz F, Adam A, Ciorubaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Comm 1974;59:1317-25
  • Neter E. Endotoxins and the immune response. Curr Top Microbiol Immunol 1969;47:82-124
  • Ribi E, Cantrell JL, Takayama K, et al. Lipid A and immunotherapy. Rev Infect Dis 1984;6:567-72
  • Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of TH1 responses. Allergy 2005;60:678-84
  • Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 1997;65:3239-47
  • Henricson BE, Manthey CL, Perera PY, et al. Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A. Infect Immun 1993;61:2325-33
  • Persing DH, Coler RN, Lacy MJ, et al. Takint toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002;10(Suppl):S32-7
  • Cluff CW, Baldridge JR, Stöver AG, et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005;73:3044-52
  • Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001;19:2400-3
  • Bienzle Günther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002;8:562-4
  • Dupont J, Altcla J, Lepetic A, et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 2006;24:7167-74
  • Harper D, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65
  • Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70
  • Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81
  • Powell E, Chow LQM. BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer. Exp Rev Resp Med 2008;2:37-45
  • Baldridge JR, McGowan P, Evans JT. Taking a toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;4:1129-38
  • Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J Endotoxin Res 2006;12:313-9
  • Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84
  • Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 1995;374:546-9
  • Sparwasser T, Vabulas RM, Villmow B, et al. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble protein. Eur J Immunol 2000;30:3591-7
  • Kim SK, Ragupathi G, Musselli C, et al. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 2000;18:597-603
  • Cooper CL, Davis H, Morris ML, et al. CpG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in nhealthy adults: a double blind phase I/II study. J Clin Immunol 2004;24:693-702
  • Siegrist CA, Philgren M, Tougne C, et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004;23:615-22
  • Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expet Opin Biol Ther 2007;7:1731-7
  • Cooper CL, Davis H, Morris ML, et al. Safety and immunogenicity of CpG 7909 injection as an adjuvant to fluarix influenza vaccine. Vaccine 2006;22:3136-43
  • Fernandez-Cruz E, Moreno S, Navarro J, et al. Therapeutic immunization with an inactivated HIV-1 immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004;22:2966-73
  • Huang KH, Boisvert MP, Chung F, et al. Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune TM vaccination prior to treatment interruption. J Immune Based Ther Vaccines 2006;4:7
  • AIDSmeds.com. IR103. Available from: http://www.aidsmeds.com/archive/IR103_1645.shtml [last accessed 2 June 2008]
  • Bernstein DI, Miller RL, Harrison CJ. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993;167:731-6
  • Harrison CJ, Miller RL, Bernstein DI. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994;38:2059-65
  • Vasilakos JP, Smith RMA, Gibson SJ, et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000;204:64-74
  • Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 2007;56:1133-41
  • Lui MA. DNA vaccines: a review. J Int Med 2003;253:402-10
  • Zuber AK, Brave A, Engström G, et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine 2004;22:1791-8
  • Otero M, Calarota SA, Felber B, et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 2004;22:1782-90
  • Thomsen LL, Topley P, Daly MG, et al. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004;22:1799-809
  • Smorlesi A, Papalini F, Orlando F, et al. Imiquimod and S-27609 as adjuvants of DNA vaccinationin a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther 2005;12:1324-32
  • Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann Rev Immunol 2000;18:245-73
  • Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003;15:138-47
  • Okada H, Tahara H, Shurin MR, et al. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intercranial neoplasms. Int J Cancer 1998;78:196-201
  • Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T cell infiltration. Cancer Res 2001;61:842-7
  • Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 2004;199:227-50
  • Rechtsteiner G, Warger T, Osterloh P, et al. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005;174:2476-80
  • Prins RM, Craft N, Bruhn KW, et al. The TLR7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 2006;176:157-63
  • Craft N, Bruhn KW, Nguyen BD, et al. The TLR7 agonist imiquimod enhances anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 2005;175:1983-90
  • Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004;5:508-15
  • Krieg AM, Efler SM, Wittpoth M, et al. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother 2004;27:460-71
  • Vicari AP, Schmalbach T, Lekstrom-Himes J, et al. Safety, pharmocokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic Toll-like receptor 9 agonist. Antivir Ther 2007;12:741-51
  • Sparwasser T, Mithke T, Lipford G, et al. Bacterial DNA causes septic shock. Nature 1997;386:336-7
  • Hasegawa K, Hayashi T. Synthetic CpG oligodeoxynucleotides accelerate the development of lupus nephritis during preactive phase In NZB × NZWF1 mice. Lupus 2003;2:838-45
  • Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003;149(Suppl 66):5-8
  • Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokonetics and safety of imiqimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004;296:6-11
  • Stefanaki C, Nicolaidou E, Hadjivassiliou M, et al. Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 2006;20:755-66
  • Mendonca CO, Yates VM. Permanent facial hypopigmentation following treatment with imiquimod cream. Clin Exp Dermatol 2006;31:721-2
  • Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment. Arch Dermatol 2005;141:908-9
  • Taylor CL, Maslen M, Kapembwa M. A case of severe eczema following use of imiquimod 5% cream. Sex Transm Infect 2006;82:227-8
  • D'Addario SD, Carrington PR. Multiple keratoakanthomas as an untoward response to imiquimod therapy for actinic keratosis. Acta Derm Venereol 2006;86:366-8
  • Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006;31:140-1
  • van der Fits L, van der Wel LI, Laman JD, et al. In psoriasis lesional skin the type I interferon signalling pathway is activated, whereas interferon-alpha-sensitivity is unaltered. J Invest Dermatol 2004;122:51-60
  • Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principle type I interferon-producing cells in human blood. Science 1999;284:1835-7
  • Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid dendritic cells following imiquimod treatment. J Natl Cancer Inst 2005;97:1143-53
  • Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells (PDC) initiate psoriasis through IFN-a production. J Exp Med 2005;202:135-43
  • Lee E, Trepicchio WL, Oesterreicher JL, et al. Increased expression of interleukin 23p19 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30
  • Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8:950-7
  • Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006;203:2577-87
  • Benson E. Imiquimod: potential risk of an immunostimulant. Australas J Dermatol 2004;45:123-4
  • Iwakura Y, Ishigame H. The IL23/IL17 axis in inflammation. J Clin Invest 2006;116:1218-22
  • Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004;16:801-7
  • Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005;202:1171-7
  • Ronnblom L, Alm GV. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001;194:F59-63
  • Pockros PJ, Guyader D, Patton H, et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007;47:174-82
  • Horsmans Y, Berg T, Desager JP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infections. Hepatology 2005;42:724-31
  • Heil F, Ahmad-Nejad P, Hemmi H, et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003;33:2987-97
  • Lee J, Chuang TH, Redecke V, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;100:6646-51
  • Lee J, Wu CCN, Lee KJ, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci USA 2006;103:1828-33
  • Gordon KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2006;174:1259-68
  • Available from: www.invivogen.com
  • Agarwala SS, Kirkwood JM, Bryant J. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer. Cytokines Cell Mol Ther 2000;6:171-6
  • Cuadros C, Lopez-Hernandez FJ, Dominguez AL, et al. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004;72:2810-6
  • Huleatt JW, Jacobs AR, Tang J, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007;25:763-75
  • Wille-Reece U, Flynn BJ, Lore K, et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005;102:15190-4
  • Huleatt JW, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal influenza caccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 lignad flagellin. Vaccine 2008;26:201-14

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.